Amgen Applies to FDA Requesting Approval of Xgeva to Treat Multiple Myeloma
Amgen submitted a supplemental Biologics Licence Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of Xgeva…
News
Genetically Modified KITE-585 Therapy Increases Survival in Mice with Myeloma, Study Shows
Kite Pharma’s genetically modified T-cell therapy KITE-585 has delayed tumor progression and increased survival in mice with multiple myeloma, according to a preclinical-trial study. The…
Stem Cell Transplant with 3-Drug Combo Improved Progression-Free, But Not Overall Myeloma Survival
Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free survival among multiple myeloma patients…
Poseida’s P-BCMA-101 Eliminates Tumors in Mice with Multiple Myeloma, Studies Show
Poseida Therapeutics‘ P-BCMA-101 eradicates tumors in mouse models of multiple myeloma and creates memory T-cells that go on the attack when the disease returns, preclinical…
Global Myeloma Action Network Declares March 30 International Myeloma Action Day
The patient-led Global Myeloma Action Network (GMAN) recently designated March 30 as International Myeloma Action Day to raise awareness of multiple myeloma, advocate for early detection and…
Leukemia & Lymphoma Society and Black Church Initiative Join to Help African-Americans with Myeloma
The Leukemia & Lymphoma Society (LLS) and the National Black Church Initiative (NBCI) are closing March, Myeloma Awareness Month, with the start of…
Multiple Myeloma Research Foundation Holds First Patient Summit in Denver
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
New Cancer Drug-delivery Vehicle May Provide More Precise Treatment, Study Shows
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s BL-8040 Shows Promise in Bone Marrow Transplants for Blood Cancers
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
Experimental LCL161 Combo Therapy Boosts Immunity and Shrinks Tumors in Myeloma Patients
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
